Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Organogenesis stock

Learn how to easily invest in Organogenesis stock.

Organogenesis is a drug manufacturers-specialty & generic business based in the US. Organogenesis shares (ORGO) are listed on the NASDAQ and all prices are listed in US Dollars. Organogenesis employs 950 staff and has a trailing 12-month revenue of around $463.9 million.

How to buy Organogenesis stock

  1. Choose a stock trading platform. Use our comparison table or choose from our Top Picks below.
  2. Open an account. Provide your personal information and sign up.
  3. Fund your account. Deposit funds unto your account by linking your banking information or transfer funds from another trading account.
  4. Search for the stock name – ORGO. Search for the stock by name or ticker symbol.
  5. Buy the stock. Place your order. It's that simple.

Best for low fees

Finder Award

SoFi Invest

  • Trade stocks for $0 and no annual fee
  • Start trading with a $0 minimum deposit
  • Get up to $1,000 when you fund a new account within 30 days

Best for beginners

Finder Award


  • Easy to use platform with low fees
  • Social trading allows you to copy popular portfolios
  • FINDER EXCLUSIVE: Get $15 when you sign up and deposit $100

Promoted for easy user experience


  • Get free stock upon signup
  • Earn 4% interest on uninvested cash with Robinhood Gold
  • Get 1% match on contributions to a Robinhood IRA

Organogenesis stock price (NASDAQ: ORGO)

Use our graph to track the performance of ORGO stocks over time.

Organogenesis shares at a glance

Information last updated 2023-02-03.
Latest market close$2.80
52-week range$2.23 - $9.27
50-day moving average $2.64
200-day moving average $4.16
Wall St. target price$11.00
PE ratio 6.1042
Dividend yield $0 (0%)
Earnings per share (TTM) $0.48

Buy Organogenesis stocks from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 6 of 6
Name Product Available asset types Stock trade fee Minimum deposit Signup bonus
SoFi Invest
Stocks, Options, ETFs, Cryptocurrency
Get up to $1,000
when you fund a new account within 30 days.
Winner of Finder’s Best Low-Cost Broker award.
Finder Award
Stocks, Options, ETFs, Cryptocurrency
when you sign up and deposit $100
Winner of Finder’s Best Broker for Beginners award. Not available in NY, NV, MN, TN, and HI.
Stocks, Options, ETFs, Cryptocurrency
Get a free stock
when you successfully sign up and link your bank account.
Make unlimited commission-free trades, plus earn 4% interest on uninvested cash in your account with Robinhood Gold.
Stocks, Options, ETFs, Cryptocurrency
Get $200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Highly commended for Best Derivatives Trading Platform award.
Stocks, ETFs, Cryptocurrency, Alternatives
Get up to $300 in either stocks or crypto
when you use code FINDERUS to sign up and fund a new account.
Trade stocks and ETFs commission-free, plus gain access to alternative investments like art, NFTs and more.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency, Futures, Forex
Winner of Finder’s Best Overall Stock Broker award.

Compare up to 4 providers

Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.

Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.

Is it a good time to buy Organogenesis stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Organogenesis price performance over time

Historical closes compared with the close of $2.8 from 2023-02-03

1 week (2023-01-30) 13.36%
1 month (2023-01-06) 6.06%
3 months (2022-11-07) -14.63%
6 months (2022-08-05) -54.77%
1 year (2022-02-07) -62.57%
2 years (2021-02-05) -78.44%
3 years (2020-02-07) 4.7
5 years (2018-02-06) 10.05

Is Organogenesis stock undervalued or overvalued?

Valuing Organogenesis stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Organogenesis's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Organogenesis's P/E ratio

Organogenesis's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 6x. In other words, Organogenesis shares trade at around 6x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Organogenesis's EBITDA

Organogenesis's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $53.4 million.

The EBITDA is a measure of a Organogenesis's overall financial performance and is widely used to measure a its profitability.

Organogenesis financials

Revenue TTM $463.9 million
Operating margin TTM 9.14%
Gross profit TTM $353.9 million
Return on assets TTM 6.4%
Return on equity TTM 26.82%
Profit margin 12.88%
Book value $1.96
Market capitalisation $383.6 million

TTM: trailing 12 months

Organogenesis share dividends

We're not expecting Organogenesis to pay a dividend over the next 12 months.

Organogenesis share price volatility

Over the last 12 months, Organogenesis's shares have ranged in value from as little as $2.23 up to $9.27. A popular way to gauge a stock's volatility is its "beta".

ORGO.US volatility(beta: 1.5)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Organogenesis's is 1.5011. This would suggest that Organogenesis's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Organogenesis overview

Organogenesis Holdings Inc. , a regenerative medicine company develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane wound covering in which viable cells growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, and cytokines; NuShield, a wound covering tissue includes both amnion and chorion membranes for spongy/intermediate layer intact; PuraPly , a antimicrobial barrier that enables conformability and fluid drainage; and Novachor, an amniotic membrane wound covering in which viable cells, growth factors/cytokines, and ECM proteins are preserved. Its surgical and sports medicine products comprise NuCel, a dehydrated placental tissue surgically applied to the target tissue to support native healing; ReNu, a cryopreserved suspension used to support healing of soft tissues; and FiberOS and OCMP used as a bone void filler primarily in orthopedic and neurosurgical applications. The company's pipeline products include PuraPly XT and PuraPly MZ to treat chronic, acute, and open wounds; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; and TransCyte, a bioengineered tissue for the treatment of partial thickness burns. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician office through direct sales force and independent agencies. The company was founded in 1985 and is headquartered in Canton, Massachusetts.

Frequently asked questions

What percentage of Organogenesis is owned by insiders or institutions?
Currently 50.572% of Organogenesis shares are held by insiders and 43.092% by institutions.
How many people work for Organogenesis?
Latest data suggests 950 work at Organogenesis.
When does the fiscal year end for Organogenesis?
Organogenesis's fiscal year ends in December.
Where is Organogenesis based?
Organogenesis's address is: 85 Dan Road, Canton, MA, United States, 02021
What is Organogenesis's ISIN number?
Organogenesis's international securities identification number is: US68621F1021
What is Organogenesis's CUSIP number?
Organogenesis's Committee on Uniform Securities Identification Procedures number is: 68621F102

More guides on Finder

Ask an Expert provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site